Summary: A new study from the University of Surrey has found that the time of day when blood samples are taken can affect the levels of Alzheimer’s biomarkers, including p-tau217, a promising marker for early dementia diagnosis. Researchers observed that these biomarkers were … [Read more...]
Alkermes Reports Q2 Advances in Narcolepsy Therapy With ALKS 2680 Results
Summary: Alkermes reported its Q2 2024 financial performance and advances in the development of narcolepsy treatments, particularly with the investigational drug ALKS 2680. The company highlighted its financial position, double-digit growth, and progress in its neuroscience … [Read more...]
Movano Submits More Clinical Results for FDA Review of Evie Ring
Summary: Movano Health and fitness has submitted up to date medical trial benefits and evidence of increased usability to the Food and drug administration as element of its 510(k) filing for the Evie Med Ring, a purchaser rest-tracking ring. Modern trials with UCSF verified the … [Read more...]
Incannex CEO: ‘Remarkable’ Results Drive Sleep Apnea Drug Trial
Summary: Incannex Health care Inc furnished an update on its stage 2/3 trials of IHL-42X, its drug candidate becoming formulated for the procedure of obstructive rest apnea (OSA), detailing preparation throughout 25 US web sites with growth plans into Europe. This proprietary … [Read more...]
Zevra Reports Positive Phase 2 Results for IH Drug Candidate
Summary: The stage 2 scientific trial of KP1077 by Zevra Therapeutics for treating idiopathic hypersomnia (IH) has yielded good leading-line effects, confirming the drug’s security and tolerability. KP1077 demonstrated important enhancements in indications these as too much … [Read more...]
Nyxoah Prepares to Unveil OSA Neurostimulation Study Results
Nyxoah SA announced the upcoming release of efficacy and safety data from the DREAM US pivotal study on the Genio neurostimulation system for obstructive sleep apnea (OSA). The results are expected by early April, according to the company’s fourth-quarter and full-year 2023 … [Read more...]